Cost-effectiveness of a specialist geriatric medical intervention for frail older people discharged from acute medical units: economic evaluation in a two-centre randomised controlled trial (AMIGOS) by Bayer, Antony et al.
RESEARCH ARTICLE
Cost-Effectiveness of a Specialist Geriatric
Medical Intervention for Frail Older People
Discharged from Acute Medical Units:
Economic Evaluation in a Two-Centre
Randomised Controlled Trial (AMIGOS)
Lukasz Tanajewski1, Matthew Franklin1, Georgios Gkountouras1, Vladislav Berdunov1,
Judi Edmans2, Simon Conroy3, Lucy E. Bradshaw2, John R. F. Gladman2, Rachel
A. Elliott1*
1 School of Pharmacy, University of Nottingham, Nottingham, United Kingdom, 2 Division of Rehabilitation
and Ageing, University of Nottingham, Nottingham, United Kingdom, 3 Universty Hospitals of Leicester,
Leicester, United Kingdom
* rachel.elliott@nottingham.ac.uk
Abstract
Background
Poor outcomes and high resource-use are observed for frail older people discharged from
acute medical units. A specialist geriatric medical intervention, to facilitate Comprehensive
Geriatric Assessment, was developed to reduce the incidence of adverse outcomes and as-
sociated high resource-use in this group in the post-discharge period.
Objective
To examine the costs and cost-effectiveness of a specialist geriatric medical intervention for
frail older people in the 90 days following discharge from an acute medical unit, compared
with standard care.
Methods
Economic evaluation was conducted alongside a two-centre randomised controlled trial
(AMIGOS). 433 patients (aged 70 or over) at risk of future health problems, discharged from
acute medical units within 72 hours of attending hospital, were recruited in two general hos-
pitals in Nottingham and Leicester, UK. Participants were randomised to the intervention,
comprising geriatrician assessment in acute units and further specialist management, or to
control where patients received no additional intervention over and above standard care.
Primary outcome was incremental cost per quality adjusted life year (QALY) gained.
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Results
We undertook cost-effectiveness analysis for 417 patients (intervention: 205). The differ-
ence in mean adjusted QALYs gained between groups at 3 months was -0.001 (95% confi-
dence interval [CI]: -0.009, 0.007). Total adjusted secondary and social care costs,
including direct costs of the intervention, at 3 months were £4412 (€5624, $6878) and
£4110 (€5239, $6408) for the intervention and standard care groups, the incremental cost
was £302 (95% CI: 193, 410) [€385, $471]. The intervention was dominated by standard
care with probability of 62%, and with 0% probability of cost-effectiveness (at £20,000/
QALY threshold).
Conclusions
The specialist geriatric medical intervention for frail older people discharged from acute
medical unit was not cost-effective. Further research on designing effective and cost-effec-
tive specialist service for frail older people discharged from acute medical units is needed.
Trial Registration
ISRCTN registry ISRCTN21800480 http://www.isrctn.com/ISRCTN21800480
Introduction
In the UK, early and rapid hospital triage of emergency patients is undertaken on acute medical
units (AMU). Many patients in AMUs have a very short length of stay (< 1–2 days), [1] and
are discharged home after assessment or a short period of stabilisation. More than 10% of all
AMU attendees are frail older people, identified by the presence of one or more geriatric syn-
dromes. [2, 3] Poor outcomes and high resource-use, observed for frail older people discharged
from AMU, [2, 4] may be avoidable. [5, 6] There is strong evidence for the effectiveness of the
process to manage frail older people known as Comprehensive Geriatric Assessment (CGA) in
general [7, 8] but little evidence for this approach applied in the urgent care context. We there-
fore developed a specialist geriatric medical intervention for older people at risk of adverse out-
comes following discharge from acute medical units, to facilitate CGA aiming to reduce the
incidence of adverse outcomes and associated high resource-use. This intervention comprised
geriatrician assessment of patients on the AMU and further short term community follow-up
to continue the assessment and oversight of the delivery of medical and non-medical
community interventions.
A randomised controlled trial (RCT) in two hospitals in Nottingham and Leicester assessed
the effectiveness of this specialist geriatric medical intervention (AMIGOS trial). [6, 9] No ef-
fect of the intervention on patient outcomes at 90 days was shown: no significant differences
between intervention and control group in days at home (primary outcome which took ac-
count of death, time spent in hospital, and any new care home placement), mortality, institu-
tionalisation, dependency, mental wellbeing, and quality of life were found. [6]
The trial also showed no significant differences in health and social care resources use be-
tween groups. [6] However, the cost consequences and cost-effectiveness of the intervention in
the AMIGOS trial have not previously been analysed. Our recent research provided innovative
costing methodology to obtain accurate hospital cost estimates in the case of frail older people
discharged from acute medical units, and to estimate both patient-level secondary and social
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care costs in the post-discharge period, [10] which we could apply to the economic evaluation
alongside the AMIGOS trial.
There are several reasons for undertaking economic evaluation in the AMIGOS trial even
though the intervention being tested showed no clinical benefit (no statistically significant ad-
vantages on its primary or secondary outcome measures). First, economic analyses in geriatric
medicine, conducted from health and social care perspectives, are important in guiding alloca-
tion of resources in elderly care. For example, a recent RCT of a specialist hospital unit for peo-
ple with delirium and dementia showed no statistically significant benefit on its primary
outcome measure [11] and yet this unit was found to be cost-saving with a very high probabili-
ty of cost effectiveness. [12] Second, subgroup economic analyses can identify potential sub-
groups of patients in whom an improved clinical intervention might be targeted and evaluated
in an appropriately powered study. Third, the evidence of the economic impact of other CGA
interventions is inconsistent [13, 14] [15]. Despite recommendations to assess opportunity
costs, [16] only few include social care costs; the eight studies reporting costs in CGA trials in a
recent review only reported costs from a hospital perspective, even though multiple health, so-
cial, private and voluntary agencies are involved in the care of frail older people which means
that they did not consider whether costs were shifted to other areas of health care, or to social
care or informal carers.[17]
The objective of this study was to assess cost consequences and cost-effectiveness of the spe-
cialist geriatric medical intervention compared to standard care, from the perspective of the
UK National Health Service and publically funded personal social care. The trial-based eco-
nomic evaluation is reported in accordance with the CHEERS Statement (S1 Appendix).
Methods
Clinical trial
A one to one parallel group individual patient RCT, Acute Medical Unit Comprehensive Geri-
atric Assessment Intervention Study (AMIGOS), was conducted. [6] The published trial proto-
col [9] and supporting CONSORT checklist are available as supporting information; see S1
Protocol and S1 Checklist, and the full report on the trial, including recruitment flow chart, is
available elsewhere as open-access article.[6]
Patients were recruited in two hospitals in Nottingham (catchment population 675 000)
and Leicestershire (catchment population 1.1 million), East Midlands, UK. Patients (aged 70 or
over) at risk of future health problems (defined by a score of at least 2/6 on the Identification of
Seniors At Risk tool [18–20]), discharged from acute medical unit (AMU) within 72 hours of
attending hospital, were eligible. Patients were excluded if they were not resident in the hospital
catchment area, as were those without capacity to give informed consent and where there was
no consultee available. Baseline clinical data collection was by interview with a researcher col-
lected from the patient, family members, or other informal or professional carers. Research
staff, not involved in recruitment or baseline data collection, and blind to allocation, deter-
mined outcomes at 90 days (±7 days) after randomisation. Routine records were examined for
mortality, changes of address, and readmission.
Standard care on the AMUs before recruitment for both the control and intervention
groups was delivered, and comprised assessment and treatment by a consultant physician and
attending medical team (and by a multidisciplinary team of physiotherapist, occupational ther-
apist and nurse, if needed). Patients’ general practitioners were responsible for all aftercare.
Participants in the control group received no additional intervention over and above standard
care. The specialist geriatric medical intervention was delivered in the intervention group. Par-
ticipants in the intervention group were assessed before discharge from the AMUs by a
Economic Evaluation of AMIGOS Trial Intervention
PLOS ONE | DOI:10.1371/journal.pone.0121340 May 5, 2015 3 / 18
geriatrician, who delivered and coordinated the delivery of any additional immediate care or af-
tercare they deemed necessary (a review of diagnoses; a drug review; further assessment at
home or in a clinic or by recommending admission rather than discharge; advance care plan-
ning; or liaison with primary care, intermediate care, and specialist community services). The
intervention was expected to be complete within one month of randomisation. Further details
of the intervention are described elsewhere.[6]
Between October 2010 and February 2012, 433 patients were recruited: 217 in the control
group and 216 in the intervention group. Sixteen participants (11 in the intervention group)
withdrawn at baseline after initial consent and were not included in clinical analysis at 90 days,
[6] nor they were included in the cost-effectiveness analysis (cost data and status (dead or
alive) at follow-up were not available for those patients). Therefore, in the trial-based economic
evaluation, 212 standard care and 205 intervention group participants were analysed at 90-day
follow-up (262/417 (63%) patients from Nottingham). Baseline characteristics of the popula-
tion and clinical effectiveness outcomes have been reported previously.[6]
Trial-based economic evaluation
Health effects. The health outcome for the cost-effectiveness analysis was quality adjusted
life years (QALYs) gained, constructing utility values from the 3-level EuroQol-5D (EQ-5D-
3L) [21] with societal weights. [22] Patient-reported EQ-5D-3L valuations at baseline and
90-day follow up (measuring health state on a scale in which 0 and 1 represent death and full
health, respectively) were applied to estimate QALYs gained, assuming baseline utility until
date of death for a patient dead at follow up. Therefore, a patient’s QALYs gained were calculat-
ed as the area under curve using linear interpolation between EQ-5D-3L measurement points,
and health outcome was summarised into a single index. Other trial health status measures, [6]
used in the imputation of missing self-reported EQ-5D-3L valuations, were: dependency in
personal activities of daily living (Barthel ADL [23]), Charlson comorbidity score [24], Identifi-
cation of Senior at Risk (ISAR) items and score [18–20], presence of geriatric conditions, and
cognitive impairment (Mini-Mental State Examination (MMSE) [25]).
Costs. To estimate cost of delivering the intervention, the interaction time of the geriatri-
cian was recorded for every patient that received the intervention, which included the duration
of interaction for: initial assessment including all related activities; home visits (travel time was
included); phone calls with the patient; and other patient related activities. Only the duration
of time spent during clinic visits was not recorded, and so a time assumption was obtained
from the PSSRU 2012. [26] The hourly cost of the geriatrician was estimated to be £132; this es-
timate includes cost aspects such as wages and on-costs, overheads, but not qualification costs,
as described in the PPSRU 2012. [26] The intervention cost was calculated for each patient
based on the recorded or assumed time spent by the geriatrician with the patient. Detail as-
sumptions and calculations are presented in Table 1.
Most health and social care services now use electronic administrative record systems to re-
cord patient care. Approvals were gained to obtain electronic administrative record systems data
from hospitals and social care in both Nottingham and Leicester. In Nottingham, further ap-
provals were obtained to gain access to general practices, ambulance services, and mental health-
care—the choice to access these extra services in Nottingham was due to the main research team
for extracting data being located in Nottingham. The time requirements and logistics for obtain-
ing access and extracting data also in Leicester were beyond the resource constraints of the
study. Data were collected for three months post-hospital discharge (July 2009—March 2012).
Based on our previous research,[10] extensive fieldwork was completed with the included agen-
cies to derive parameters covering resource-use (details in S2 Appendix).
Economic Evaluation of AMIGOS Trial Intervention
PLOS ONE | DOI:10.1371/journal.pone.0121340 May 5, 2015 4 / 18
Hospital care data (day-case, inpatient, outpatient and intensive care) were obtained from
two patient administration systems for patients that attended five hospitals in Nottingham.
The Secondary Users Service (SUS) database was interrogated to obtain day-case, inpatient and
outpatient data in Leicester—intensive care data was not available from this database.
Primary care resource-use data were obtained from Nottingham and Nottinghamshire GP
practices. Of 84 GP practices serving our cohort, data were obtained from 53 practices (192/
262 participants), coming from five electronic administrative record systems: SystmOne, 109
(57%); EMIS LV, 59 (31%); EMIS Web, 17 (9%); Synergy, 5 (3%); and EMIS PCS, 2 (1%), and
were anonymised at the GP practice.
Ambulance service resource-use was extracted from the Caller Aided Despatch (CAD) IT
service. The CAD system was cross-referenced with paper-based Patient Record Forms to iden-
tify participants (using participant name and place of pick-up). Data from mental healthcare
services for older people were provided by the Nottinghamshire Healthcare Trust data via the
RiO system. [27] Social care services within two different catchment areas in Nottingham (City
and County), operating two different electronic systems, were identified. Services consisted of
contacts and assessments, and care plans. Care plans included home, day, residential and tele-
phone care, housing and meals-on-wheels. Similarly, social care data were collected from two
catchment areas (City and County) in Leicester.
Unit costs for primary care services were applied based on time taken to perform each task
using time assumptions obtained from PSSRU 2011/12, [28] empirical literature, or expert
opinion, and mid-point yearly salary estimations taken from the NHS “Agenda for Change”
pay rates. [29] Unit costs of hospital care were applied using national reference costs according
to Healthcare Resource Group (HRG) case-mix. Inpatient spell costs were adjusted for length-
of-stay using standard excess bed day costs. Unit costs for other services were obtained from
PSSRU, standard Department of Health costs and other reference costs for the 2011/12 finan-
cial year. [26] The detail costing methods are described elsewhere, [10] and the sources of unit
costs are presented in S2 Appendix.
Unit costs were combined with resource-use to generate patient-level costs. Patient-level
secondary (inpatient, daycase, outpatient) and social care cost, collected for both sites, incurred
Table 1. Cost of specialist geriatric medical intervention.
Type of
interactiona
Mean interaction duration (hours)b
(median, min, max, 95% CI)
Mean cost of each interaction (£)cd
(median, min, max, 95% CI)
Initial Assessment 0.77 (0.75, 0.08, 5, 0.72–0.83) 99 (99, 0, 660, 91–106)
Home visits 0.56 (0, 0, 2, 0.46–0.65) 73 (0, 0, 264, 61–86)
Phone calls 0.25 (0.17, 0.03, 1, 0.21–0.3) 9 (0, 0, 132, 6–12)
Clinic visitse 0.02 (0, 0, 0.57, 0.01–0.03) 3 (0, 0, 76, 1–5)
Other activities 0.18 (0, 0, 2.5, 0.14–0.23) 24 (0, 0, 330, 18–30)
Mean intervention
costf
208 (186, 0, 660, 192–227)
aAll of the interactions assume involvement of geriatricians’ time only.
bTime expressed in hours.
cHourly wage based on the value of contract hour reported in PSSRU §15.5, p. 235 (PSSRU 2012 [26]),
equal to £132.
dEqual to Mean duration of interaction × Hourly wage.
eIt was assumed that clinic visits last 17.2 minutes as in PSSRU §10.8b, p. 183 (PSSRU 2012 [26]).
fIn the full sample (205 patients in the intervention group). Mean costs in complete-case sample and in
other subgroups analysed are presented in Table 3 and S3 Appendix.
doi:10.1371/journal.pone.0121340.t001
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during the trial period were calculated for all trial participants who remained in the study at
90-day follow-up (patients who died during the study were not classed as ‘withdrawn’). Critical
care, ambulance service, Mental Health Trust, and primary care costs, omitted in the two-cen-
tre cost-effectiveness analysis, were analysed for the Nottingham sub-sample.
Statistical analysis. The economic evaluation adopted a secondary (inpatient, daycase,
outpatient) and social care perspective. The incremental cost-effectiveness ratio (ICER) gener-
ated by the intervention over standard care was calculated using the following equation:
ICER ¼ CostInt  CostSC
QALYInt  QALYSC
;
where CostInt (CostSC) and QALYInt (QALYSC) are mean cost and QALYs gained in the inter-
vention (standard care) group, respectively. Patient cost and QALYs were adjusted by baseline
characteristics using regression methods, pairwise bootstrapping with replacement was em-
ployed for adjusted patient costs and QALYs using 5000 replications, and the resultant incre-
mental costs and QALYs were plotted on a cost-effectiveness plane. [30] Uncertainty around
ICERs was investigated and cost effectiveness acceptability curves [31] [32] were constructed.
The analyses were performed using STATA version 12 [33] and Microsoft Excel 2010.
Missing data for patient-reported EQ-5D-3L are: 84/417 (20.1%) baseline EQ-5D-3L, 106/
417 (25.4%) follow-up EQ-5D-3L, resulting in QALYs obtained for 254/417 (60.9%) partici-
pants, including 16 (intervention: 8) dead at follow up. No statistically significant differences in
the percentages of missing EQ-5D-3L and QALYs values between the intervention and stan-
dard care groups were observed: 43/205 (21.0%) vs. 41/212 (19.3%), p = 0.68, for baseline EQ-
5D-3L; 45/205 (22.0%) vs 61/212(28.8%), p = 0.11, for follow-up EQ-5D-3L; and 78/205
(38.0%) vs 85/212 (40.1%), p = 0.67, for QALYs.
Missing EQ-5D-3L valuations were imputed using multiple imputation by chained equa-
tions, [34] incorporating the set of variables: age and sex; Charlson comorbidity (scores 2–3
and4), 6 items of Identification of Senior at Risk (ISAR) tool, presence of geriatric condi-
tions, cognitive impairment (Mini-Mental State Examination (MMSE) score), and permanent
care home residence at baseline; Barthel Activities of Daily Living (ADL) score at baseline and
follow-up, and hospital location; inpatient, day-case, outpatient, and social care costs. Forty
five imputed datasets were generated; based on rule of thumb, number of imputations was
equal to the percentage of patients with at least one variable in the imputation model missing,
45% (apart from missing EQ-5D-3L data, Barthel ADL scores were missing at baseline and fol-
low up, 14% and 26%, respectively).
Secondary (inpatient, daycase, outpatient) and social care cost data, collected for both Not-
tingham and Leicester sites, and analysed in economic evaluation, were complete. In the Not-
tingham sample, cost data for all health services were complete, except primary care data
missing for 70/262 (26.7%) patients.
In the full-sample cost-effectiveness analysis (CEA), imputed missing EQ-5D-3L valuations
data were incorporated into generation of QALYs gained. Additionally, imputed baseline utili-
ty values were included as covariate in the adjustment models. Adjusted cost and QALYs were
estimated controlling for age, sex, hospital location, and baseline utility (cost was additionally
adjusted by Charlson co-morbidity (scores 2–3 and4) and residence at care home). Adjust-
ment models and diagnostic tests were calculated on each imputed dataset, to obtain adjusted
cost and QALYs averaged across 45 imputations (Rubin’s rules), and to find the optimal gener-
alized linear models (GLMs) for both costs and QALYs (considering the worst test result across
imputations) [34]. Adjusted cost, calculated using the recycled prediction method, [30] and ad-
justed QALYs, obtained from ordinary least squares (OLS) regression, were used to generate
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cost-effectiveness plane and cost effectiveness acceptability curve on each imputed dataset. Full
sample cost effectiveness acceptability curve was obtained from probability of cost-effective-
ness for given willingness to pay, averaged across 45 imputations.
Complete-case CEA was undertaken, comprising 254/417 (60.9%) patients with complete
QALY data. Adjusted cost and QALYs were estimated controlling for age, sex, and baseline
utility, Charlson co-morbidity (scores 2–3 and4), higher risk of future health problems (4
on Identification of Senior at Risk (ISAR) tool), and hospital location (cost was additionally ad-
justed by residence at care home at baseline). A diagnostic process was used to find the optimal
GLM for both costs and QALYs; recycled prediction method [30] and OLS regression were
used to generate adjusted patient cost and QALYs, respectively.
Cost analyses were conducted for the full sample (inpatient, daycase, and outpatient care)
and for the Nottingham sample (incorporating complete-case resource-use dataset, 192/262
(73.3%) patients). Costs in the intervention and standard care arms, as well as incremental
costs by services were estimated, handling uncertainty by non-parametric bootstrapping (95%
confidence intervals around the point estimates were calculated using bias-corrected nonpara-
metric bootstrap with 2500 replications).
The pre-planned subgroup analyses according to risk of future health problems (defined by
ISAR score) and care home residence, as prognostically important baseline indicators of out-
comes specified in the trial protocol (S1 Protocol), [9] were carried out. Cost analyses were con-
ducted for moderate-risk patients defined as those with a score of 2ISAR<4 (all trial
participants: 2ISAR6, higher-risk patients: ISAR4), and for care home residents: 254 (in-
tervention: 122) and 108 (intervention: 52) participants, respectively. Net-benefit regression
approach was applied to investigate subgroup effect on cost-effectiveness of the intervention,
accounting for baseline characteristics and intervention-covariate interactions. [35] The pa-
tient-level net benefit (nb), calculated using the following equation,
nbðlÞ ¼ lE  C;
where E and C are the patient’s observed effect (QALYs) and total cost, respectively, was ana-
lysed in regression models for different willingness to pay thresholds (λ). Thus, the net mone-
tary beneﬁt (NMB) generated by the intervention over standard care,
NMBðlÞ ¼ ðlQALYInt  CostIntÞ
|ﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ}
mean nb in the intervention group
 ðlQALYSC  CostSCÞ
|ﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ}
mean nb in the standard care group
¼ lðQALYInt  QALYSCÞ  ðCostInt  CostSCÞ;
adjusted by age, sex, baseline utility, Charlson co-morbidity (scores 2–3 and4), higher risk of
future health problems (4 on ISAR tool), and no-care-home residence, with age- and utility-
intervention interactions, was estimated for the whole group, and for the subgroups (incorpo-
rating additionally intervention-higher-risk (ISAR4) or intervention-no-care-home interac-
tion terms in the regression, respectively). Cost effectiveness acceptability curves were drawn
based on p-values for intervention coefﬁcients in the regression models (reﬂecting the decision
rule that the intervention should be implemented over standard care, at given threshold (λ), if
NMB (λ)> 0). Net-beneﬁt regression results for £20,000 threshold were presented.
Full sample net-benefit regression analysis was conducted, incorporating imputed missing
EQ-5D-3L valuations data: diagnostic tests were calculated on each imputed dataset (consider-
ing the worst test result across imputations), Rubin’s rules were applied to obtain regression re-
sults over 45 imputation.[34]
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Results
Intervention cost
In the full sample, mean per-patient cost of delivering the intervention was £208 (95% confi-
dence interval [CI]: 192, 227). Initial assessments and home visits were major cost drivers of
the intervention, with mean costs £99 (95% CI: 91, 106) and £73 (95% CI: 61, 86), respectively.
Calculations are presented in Table 1.
Full-sample using imputed data cost-effectiveness analysis
In the full-sample cost-effectiveness analysis (CEA), 417 (intervention: 205) participants were
analysed at 90-day follow-up, at which point 26 (intervention: 14) were dead. Comparing the
intervention to control, mean total cost was non-significantly higher (£419, 95% CI: -597,
1371) and the difference in mean QALYs gained was 0.003 (95% CI: -0.012, 0.017). In adjusted
cost-effectiveness analysis, total cost for the intervention group was significantly higher (£302,
95% CI: 193, 410) and QALYs gained difference was -0.001 (95% CI: -0.009, 0.007), with 0%
probabilities of cost-effectiveness (ICER £20,000/QALY) and dominance. The probability
that the intervention was dominated by standard care was 62%. (Table 2 and Fig 1).
Complete-case cost-effectiveness analysis
In the subgroup of 254 (intervention: 127) patients with complete EQ-5D-3L data, including
16 (intervention: 8) patients dead at follow up, comparing the intervention and control groups,
mean total cost was non-significantly higher (£228, 95% CI: -1203, 1527) and the difference in
QALYs gained was 0.004 (95% CI: -0.012, 0.020). In adjusted cost-effectiveness analysis, total
cost for the intervention group was significantly higher (£235, 95% CI: 21, 445) with QALYs
gained difference equal to 0.002 (95% CI: -0.006, 0.011), ICER (£116,326/QALY, 95% CI:
£13,900 to1), and 1% probability of the intervention being dominant and 8% probability of
Table 2. Full-sample cost-effectiveness analysis (mean cost in £ / mean QALY, 95% CI).
Intervention (205
patients)
Standard care (212
patients)
Incremental cost / QALYs
gained
The cost of carea 4267 (3697, 4934) 4057 (3367, 4882) 210 (-809, 1165)
The cost of care—adjustedb 4203 (4130, 4276) 4110 (4037, 4182) 94 (-10, 198)
The intervention cost 208 (192, 227) 0 208 (192, 227)
Total cost (care cost + intervention cost) 4475 (3901, 5141) 4057 (3367, 4882) 419 (-597, 1371)
Total cost—adjusted (care cost adjusted + intervention
cost)
4412 (4331, 4490) 4110 (4037, 4182) 302 (193, 410)
QALYs gained 0.107 (0.097, 0.118) 0.103 (0.093, 0.112) 0.003 (-0.012, 0.017)
QALYs gained—adjustedc 0.106 (0.100, 0.115) 0.107 (0.098, 0.113) -0.001 (-0.009, 0.007)
ICER £147 087/QALY
ICER adjusted The intervention dominated by standard care
Multiple imputation by chained equation (MICE): predictive mean matching (pmm) for utilities and ordered logit (ologit) for Barthel ADL scores;
45 imputations.
aInpatient, day-case and outpatient cost data were collected for both locations, Nottingham and Leicester.
bAdjusted by age, sex, hospital location (Leicester), and baseline utility, permanent care home residence, and Charlson co-morbidity (scores 2–3 and 4).
A GLM model (family—gamma, link—0.8) was applied.
c Adjusted by age, sex, hospital location (Leicester), and baseline utility. OLS was applied.
doi:10.1371/journal.pone.0121340.t002
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ICER £20,000/QALY; the probability that the intervention was dominated by the control
was 28%. (Table 3 and Fig 1 and 2).
Cost analyses
In the full-sample of 417 (intervention: 205; Nottingham: 262), comparing the intervention
and control groups, the cost of inpatient care was non-significantly lower (-£212, 95% CI:
-1019, 537), day-case cost was significantly higher, £156 (95% CI: 36, 278), outpatient care
Table 3. Complete-case cost-effectiveness analysis (mean cost in £ / mean QALY, 95%CI).
Intervention (127
patients)
Standard care (127
patients)
Incremental cost / QALYs
gained
The cost of carea 4114 (3417, 4956) 4085 (3145, 5297) 29 (-1386, 1333)
The cost of care—adjustedb 4139 (4004, 4289) 4103 (3969, 4252) 36 (-159, 232)
The intervention cost 199 (178, 217) 0 199 (178, 217)
Total cost (care cost + intervention cost) 4312 (3612, 5153) 4085 (3145, 5297) 228 (-1203, 1527)
Total cost—adjusted (care cost adjusted + intervention
cost)
4338 (4187, 4490) 4103 (3957, 4249) 235 (21, 445)
QALYs gained 0.120 (0.108, 0.133) 0.117 (0.105, 0.129) 0.004 (-0.012, 0.020)
QALYs gained—adjustedc 0.125 (0.120, 0.131) 0.123 (0.117, 0.129) 0.002 (-0.006, 0.011)
ICER £63 559/QALY
ICER adjusted £116 326/QALYd
aInpatient, day-case and outpatient cost data were collected for both locations, Nottingham and Leicester.
bAdjusted by age, sex, hospital location (Leicester), and baseline utility, permanent care home residence, Charlson co-morbidity (scores 2–3 and 4), and
higher risk of future health problems at admission (4 on Identiﬁcation of Senior at Risk (ISAR) tool). A GLM model (family—gamma, link—0.45)
was applied.
cOLS was applied (adjustment covariates as above, except care home residence at baseline).
dFrom CEAC (Fig 1) we know that 95% CI for ICER is £13,900-1.
doi:10.1371/journal.pone.0121340.t003
Fig 1. Cost-effectiveness acceptability curves (adjusted analyses, full sample). Full-sample CEAC is
obtained from probability of cost-effectiveness for givenWTP, averaged across 45 imputations.
doi:10.1371/journal.pone.0121340.g001
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costs was non-significantly higher, £46 (95% CI: -78, 167), and social care cost was non-signifi-
cantly higher (£220, 95% CI: -270, 706), resulting in the cost of (secondary and social) care in
the intervention group being non-significantly higher by £210 (95% CI: -809, 1156), and with
an incremental total cost of £419 (95% CI: -597, 1371). (Table 4).
In the subgroup of the Nottingham sample, comprising 192 (intervention: 95) patients with
complete resource-use data, comparing the intervention to standard care, the cost of inpatient
care was non-significantly lower (-£121, 95% CI: -1152, 1016), day-case care and outpatient
costs were higher, £203 (95% CI: 55, 379) and £91 (95% CI: -969, 1324), respectively, and social
care cost was significantly higher (£850, 95% CI: 120, 1606). The incremental cost for primary
and tertiary care services, for which resource data were not collected for the Leicester sample,
was -£12 (95% CI: -143, 119); primary care cost was non-significantly higher in the interven-
tion group (£38, 95% CI: -25, 101). Comparing the intervention to standard care, the total care
cost was non-significantly higher by £1010 (95% CI: -445, 2420), and the incremental cost was
£1251 (95% CI: -211, 2650). (S3 Appendix, Table A).
Subgroup and net monetary benefit analyses
Comparing the intervention to standard care in the subgroup of 254 (intervention: 122) partici-
pants who were classed as moderate-risk patients at baseline admission (<4 at ISAR tool), the
inpatient cost was non-significantly lower (-£438, 95% CI: -1580, 668), day-case and outpatient
care costs were higher, £146 (95% CI: 21, 282) and £53 (95% CI: -108, 223), respectively, and
social care cost was non-significantly higher (£43, 95% CI: -430, 592), resulting in non-signifi-
cantly lower cost of (secondary and social) care (-£196, 95% CI: -1487, 1060), and non-signifi-
cantly lower total cost (-£6, 95% CI: -1295, 1251). (S3 Appendix, Table B). In the subgroup of
108 (intervention: 52) permanent care home residents at baseline, comparing the intervention
to standard care, inpatient and social care costs were non-significantly lower (-£186 (95% CI:
-1141, 765) and -£320 (95% CI: -1664, 948), respectively), resulting in non-significantly lower
care cost (-£419, 95% CI: -2130, 1208), and non-significantly lower total cost (-£173, 95% CI:
-1811, 1464). (S3 Appendix, Table C).
Fig 2. Cost-effectiveness plane—pairwise bootstrapping (adjusted analysis, complete-case sample).
doi:10.1371/journal.pone.0121340.g002
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In the whole group, at £20,000/QALY willingness to pay, comparing the intervention to
standard care, the adjusted net monetary benefit (NMB) was -£423 (95% CI: -1425, 580;
p = 0.41), with 20% probability of cost-effectiveness. Net-benefit regression showed significant
association for utility at baseline (p = 0.01), and significantly higher net benefit for Leicester
sub-sample compared to Nottingham sub-sample (£1278, 95% CI: 293, 2263; p = 0.01). The lat-
ter is the consequence of significantly lower healthcare costs in the Leicester sub-sample, com-
pared with the Nottingham sub-sample (-£1300, 95% CI: -2019, -516) (see footnotes
underneath Table 4 for further detail and explanation). Net benefit for higher-risk patients
(ISAR4) was lower compared to moderate-risk patients (-£997, 95% CI: -62, 2057; p = 0.06)
(Model 1 presented in Table 5 and Fig 3).
Net-benefit regression (at £20,000/QALY willingness to pay), according to risk of future
health problems at admission (defined by ISAR tool) showed that, comparing the intervention
to standard care: (i) in the subgroup of 254 (intervention: 122) moderate-risk patients
(ISAR<4), the NMB was -£144 (95% CI: -1446, 1158; p = 0.83), with 41% probability of cost-
effectiveness; (ii) in the subgroup of 163 (intervention: 83) higher-risk patients (ISAR4), the
NMB was -£852 (95% CI: -2435, 732; p = 0.29), with 15% probability of cost-effectiveness. The
NMB, generated by the specialist geriatric medical intervention over standard care, was non-
significantly lower for high-risk patients, compared to moderate-risk patients (-£707, 95% CI:
-2763, 1348; p = 0.50). (Model 2 presented in Table 5 and Fig 3).
Net-benefit regression (at £20,000/QALY willingness to pay), according to baseline care
home residence showed that, comparing the intervention to standard care: (i) in the subgroup
Table 4. Full-sample two-center cost analysis (mean cost in £, 95% CI).
Intervention (205 patients) Standard care (212 patients) Incremental cost
Inpatient cost 1477 (1060, 2016) 1689 (1131, 2359) -212 (-1019, 537)
Day-case cost 1134 (1047, 1233) 979 (908, 1061) 156 (36, 278)
Outpatient cost 470 (391, 563) 424 (345, 509) 46 (-78, 167)
Total healthcare costa 3081 (2636, 3633) 3091 (2502, 3806) -10 (-860, 763)
Social care costb 1186 (864, 1586) 966 (652, 1344) 220 (-270, 706)
The cost of care 4267 (3697, 4934) 4057 (3367, 4882) 210 (-809, 1165)
The intervention cost 208 (192, 227) 0 208 (192, 227)
Total cost (care cost + intervention cost) 4475 (3901, 5141) 4057 (3367, 4882) 419 (-597, 1371)
aInpatient, day-case and outpatient cost data were collected for both locations, Nottingham and Leicester. The mean healthcare cost for the Nottingham
sample was £3569 (95%CI: 3068, 4220), the mean healthcare cost for the Leicester sample was £2269 (95%CI: 1854, 2810), with healthcare cost
signiﬁcantly lower in the Leicester sample by -£1300 (95% CI: -2019, -516). This statistically signiﬁcant difference may be attributed to signiﬁcantly higher
percentage of care home residents in the Leicester sub-sample (34.2% vs. 21.0%, p < 0.01), for whom healthcare cost was signiﬁcantly lower than for
non-residents in the whole sample (by -£880 (95%CI: -1631, -192)), to other non-observable differences between Leicester and Nottingham patient
populations, as well as to different coding systems between sites (S2 Appendix). The two centre retrospective resource use datasets obtained for this
study, and for related previous cost cohort study, [10] did not allow us to ascertain the latter hypothesis and explain fully the reasons of the difference in
secondary care costs between Nottingham and Leicester.
bThe mean social care cost for the Nottingham sample was £1010 (95%CI: 720, 1338), the mean social care cost for the Leicester sample was £1183
(95%CI: 770, 1652), with social care cost non-signiﬁcantly higher in the Leicester sample by £173 (95% CI: -354, 726). Despite signiﬁcantly higher
percentage of care home residents in Leicester sample, for whom social care cost was higher than for non-residents in the whole sample (by £1026 (95%
CI: 361, 1026)), social care cost in Leicester was not higher signiﬁcantly and was not higher enough to reduce the overall difference in costs between
sites. The reason could be that in the Leicester sample the percentage of patients living alone was signiﬁcantly lower than in the Nottingham sample
(31.0% vs. 46.6%, p < 0.01), and in the whole sample social care costs for those living alone was signiﬁcantly higher by £804 (95%CI: 381, 1283), when
comparing to those living with spouse. Social care costs was £366 (95%CI: 146, 585), £1170 (95%CI: 817, 1603), and £1835 (95%CI: 1209, 2517), for
living with spouse, for living alone, and for care home residents, respectively.
doi:10.1371/journal.pone.0121340.t004
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of 108 (intervention: 52) care home residents, the NMB was £437 (95% CI: -1704, 2578;
p = 0.69), with 66% probability of cost-effectiveness; (ii) in the subgroup of 309 (intervention:
153) patients living in a non-institutional setting, the NMB was -£724 (95% CI: -1915, 468;
p = 0.23), with 12% probability of cost-effectiveness. The NMB, generated by the intervention
over standard care, was non-significantly lower for patients living in a non-institutional setting,
compared to care home residents (-£1161, 95% CI: -3696, 1375; p = 0.37). (Model 3 presented
in Table 5 and Fig 3).
Discussion
Summary of findings
This study confirmed that the specialist geriatric medical intervention for at risk older people
discharged from acute medical units as tested in the AMIGOS study did not demonstrate bene-
fits in health status, as no significant effect on QALY gain was observed. This study showed
that the total cost for participants who received the intervention was higher than for those re-
ceiving standard care. The intervention was not cost-effective, and probability that it was domi-
nated by standard care (more costs and less QALY) was high. Subgroup analyses did not
identify any group in which there was a significant advantage of the intervention over the con-
trol, although there were trends towards greater cost-effectiveness of the intervention in care
home residents and moderate-risk (but not high risk) patients (2ISAR<4). Comparing the
intervention to standard care, cost savings for inpatient care and higher costs for social, day
case and outpatient care were observed (however, these unadjusted cost differences were non-
significant, except day case care).
Fig 3. Cost-effectiveness acceptability curves (subgroups and overall, net-benefit regression
approach). CEACs obtained from p-values, p, for intervention coefficient in net-benefit regressions for
WTP£4,000 (for which Prob(>F)<0.05). In the case of negative coefficient, probability of cost-effectiveness
is equal to p/2, in the case of positive, 1—p/2. Regression models analogical to those presented in Table 5,
£1000-intervals for subsequent WTP applied. Due to model specification tests failed for WTP<£15,000,
CEACs for care home subgroups are presented starting fromWTP = £15,000.
doi:10.1371/journal.pone.0121340.g003
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Strengths and limitations: internal validity
The strengths of this study were that it was conducted as an independent but pre-planned part
of a RCT, [6, 9] and that resource-use data collection from various electronic systems and cost-
ing methods (tested previously in [10]) allowed accurate cost estimates to be produced. We ap-
plied EQ-5D-3L valuations to estimate QALYs due to its relevance for the UK policy makers.
There were considerable EQ-5D-3L missing data at baseline and follow up, due to inability of
frail older people, recently discharged from an acute medical care unit and in the post-dis-
charge period, to complete EQ-5D-3L questionnaires. Additionally, 27% and 16% of partici-
pants had a prior dementia diagnosis and presented with cognitive impairment/confusion at
baseline, respectively, [6] which is likely to have negatively affected the EQ-5D-3L question-
naire response rate. The large set of clinical measures collected as part of RCT enabled imputa-
tion methods to deal with missing EQ-5D-3L data. Economic evaluation of such complex
services needs to consider broader outcomes than the QALY, however other health and well-
being potential benefits of the intervention were investigated previously in the RCT, [6] and no
benefits were shown. A weakness was that full resource-use data were collected from only one
of the two centres of the AMIGOS study, thereby limiting the analysis to the secondary care
and social service perspective and reducing the precision of the findings. However, it did not af-
fect the main findings because primary and tertiary care accounted for 1% of the difference in
total costs in the Nottingham sample. Another limitation was that the study sample was too
small to conduct stratified cost-effectiveness analysis, and to provide convincing findings from
subgroup analyses.
Findings in context: external validity
AMIGOS was one of the few studies to examine the value of a specialist geriatric medical inter-
vention to at risk patients on acute medical units (AMUs), and this is the only economic study
of this approach. There is evidence that comprehensive geriatric assessment (CGA) is effective
in older people, including acute care settings. [36, 37] However, the cost-effectiveness studies
on CGA are limited, [13, 14] [15] and the economic value of CGA in the urgent care context
was not yet known. The question how healthcare services can be configured to deliver high
quality and efficient acute care for frail older people remains a challenge, and new forms of
AMU services for older people which improve efficiency without adversely affecting mortality
or re-admission rates merit further investigation. [38] The AMIGOS intervention was an at-
tempt to deal with these needs, but despite no negative effect on mortality or re-admission, [6]
the overall economic impact of this intervention was shown to be unfavourable.
Interpretation
This study illustrates that although there are reasons to anticipate that specialist medical inter-
vention might demonstrate clinical and economic advantages over standard medical care for at
risk older people in acute medical units, these may not be seen when tested rigorously. The re-
sults presented here suggest there is a reasonable chance that standard treatment could be eco-
nomically preferable. Thus, those developing, commissioning and providing such specialist
services should carefully evaluate them and they should be seen as experimental until better
models of care are developed that demonstrate robust evidence of effectiveness and cost-effec-
tiveness. We had previously suggested that developments of this approach should consider tar-
geting of the intervention upon higher-risk patients. [6] These results do not support this
suggestion because there was a trend towards lower cost-effectiveness of the intervention in
higher-risk group (ISAR4), compared to moderate-risk patients (2ISAR<4).
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However, given the tendency towards better results in patients living in care homes, it is rea-
sonable to consider developments of services focussed upon this group of patients and integrat-
ed with this sector of care. That is, in this sub-group of patients, the higher social care costs in
the intervention arm were reversed to demonstrate some cost savings, resulting in favourable
overall cost comparisons and a trend toward cost-effectiveness. This could be the consequence
of the explicit intervention components of advance care planning or end of life care. These
were more efficient for care home patients who were already primed for these events (more
than patients living in their own homes). It is likely that, in the case of care home residents, so-
cial care resource use structure prior to the intervention made it possible to reduce spending as
intended by other intervention components (social care maintenance costs), and keeping un-
changed the costs that had already occurred (advance care planning). The (pre-planned) sub-
group analysis (net benefit regression), supported by the above post hoc explanation of social
care costs differences, suggests that the intervention targeted at patients admitted from care
homes (or offered at care homes after a short stay at acute medical unit) might result in social
care costs savings, overall cost reduction, and might be cost-effective. Hence, the specialist geri-
atric medical intervention is worth further evaluation in an appropriately powered study, in a
larger population of care home residents.
Whilst the findings were not statistically significant, some savings were observed for inpa-
tient care, and higher costs occurred for social, day-case and outpatient care, when comparing
the intervention to standard care. The trade-off between inpatient stay and social care (com-
bined with day-case hospitalizations and outpatient visits) was critical for the overall cost con-
sequences and cost-effectiveness of the intervention. This observation demonstrates the need
for inclusion of the social care perspective in economic evaluations of specialist services for
older people, as reporting only hospital or secondary care costs would not depict the true eco-
nomic impact of such services. The intervention was intended to limit the need for social care
maintenance costs, but it did not reduce resource use in this sector, [6] as we showed higher
overall costs occurred for social care in the intervention arm, resulting in unfavourable cost-ef-
fectiveness of the new service.
One of the explicit components of the intervention was to make use of outpatient and day
case care to try to reduce subsequent health deterioration, the need for acute care, and readmis-
sions. This study showed significantly higher costs of day case care and non-significantly
higher costs of outpatient care, in the intervention arm, compared with standard care; the same
patterns were observed for all sub-groups analysed as well. These findings are in line with the
strategy of the delivery of medical interventions within the new model of care. Although some
savings were observed for inpatient care (non-significant differences between groups), which
might be the intended effect of more intensive use of day case and outpatient care, the overall
economic impact of the intervention was negative and was driven by its effect on social care
costs. The above discussion on the subgroup of care home residents, for whom the structure of
social care spending is different, supports this notion.
This study provides evidence to guide resource use data collection for future economic eval-
uations of geriatric hospital services. The negligible impact of primary care on theoverall cost
of the intervention suggests that resource use data from this sector of care might not be worth
collecting and costing in future research; this process was found to be extremely time consum-
ing and expensive and so this study provides the argument that more time and effort should be
put into secondary and social care cost data. The large differences in secondary care costs be-
tween Nottingham and Leicester and different costs of the intervention between the two sites
(suggested by the Nottingham sub-sample cost analysis for all services) confirm the value of
the two-centre trial and justify the need for multicentre studies to obtain more generalisable re-
sults on cost-effectiveness.
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